Is clozapine selective for the dopamine D4 receptor?

Area of Science:

• Neuroscience
• Pharmacology

Background:

• Dopamine receptors, specifically D2 and D4 subtypes, are crucial targets for antipsychotic medications.
• Understanding the binding affinities of various drugs to these receptors is essential for developing effective treatments.

Purpose of the Study:

• To investigate the binding characteristics of radioligands 3H-spiperone and 3H-raclopride to human dopamine D2 and D4 receptors.
• To evaluate the inhibitory effects of clozapine, spiperone, (-) eticlopride, haloperidol, and 1192U90 on these receptor binding sites.

Main Methods:

• Utilized cell membranes stably transfected with human dopamine D2 and D4 receptor clones.
• Performed radioligand binding assays using 3H-spiperone and 3H-raclopride.
• Assessed drug inhibition of radioligand binding to determine binding affinities (Ki ratios).

Main Results:

• 3H-spiperone and 3H-raclopride labeled equivalent sites on the D2 receptor preparation.
• Clozapine and the novel benzamide 1192U90 demonstrated greater inhibition of 3H-raclopride binding than 3H-spiperone binding to the D2 receptor.
• Clozapine and 1192U90 exhibited apparent selectivity for the D4 receptor over the D2 receptor when assessed by Ki ratios against 3H-spiperone binding, but not 3H-raclopride binding.

Conclusions:

• The study elucidates differential binding affinities of key compounds to dopamine D2 and D4 receptors.
• Findings suggest that clozapine and 1192U90 may possess a degree of selectivity for the D4 receptor subtype.
• This receptor selectivity profile is critical for understanding the pharmacological actions and potential therapeutic applications of these agents.